
<!doctype html>
<html>
<head id="header"><title>
	Targeted Cancer Therapies Fact Sheet - National Cancer Institute
</title><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<!-- This is to make content width follow different rules for IE7 and below -->
<!--[if lt IE 8]>
<style type="text/css">
.contentzone-defaultTemplateContentContainer{
	width: 650px !important;
	padding-right: 50px !important;
}
.cgvBody-defaultTemplateContentContainer {
	padding-right: 0 !important;
  width: auto !important;
}
ul.ctpListPageList {
	width: 400px !important;
}
</style>
<![endif]-->
<link href="/PublishedContent/Styles/nci.css" rel="stylesheet" /><link href="/PublishedContent/Styles/nci-new.css" rel="stylesheet" /><link href="/PublishedContent/Styles/nciplus.css" rel="stylesheet" /><link href="/PublishedContent/Styles/emergency_IE.css" rel="stylesheet" /><link href="/PublishedContent/Styles/jquery-ui-1.8.5.custom.css" rel="stylesheet" /><link href="/PublishedContent/Styles/print_nci.css" rel="stylesheet" /><script src="/PublishedContent/js/imgEvents.js" type="text/javascript"></script><script src="/PublishedContent/js/popEvents.js" type="text/javascript"></script><script src="http://ajax.googleapis.com/ajax/libs/jquery/1.5.1/jquery.min.js" type="text/javascript"></script><script src="/PublishedContent/js/jquery-widgets.js" type="text/javascript"></script><script src="/PublishedContent/js/jquery-ui-1.8.5.custom.min.js" type="text/javascript"></script><script src="/PublishedContent/js/JSLoader.js" type="text/javascript"></script><script src="/PublishedContent/js/jquery.ui.position.js" type="text/javascript"></script><script src="/PublishedContent/js/jquery.ui.autocomplete.js" type="text/javascript"></script><script src="/PublishedContent/js/sw-autocomplete.js" type="text/javascript"></script><script src="https://ajax.googleapis.com/ajax/libs/swfobject/2.2/swfobject.js" type="text/javascript"></script><script src="/PublishedContent/js/NCIGeneralJS.js" type="text/javascript"></script><script src="/PublishedContent/js/modernizr.custom.2.7.1.js" type="text/javascript"></script><script src="/PublishedContent/js/Enlarge.js" type="text/javascript"></script><script src="/PublishedContent/js/STOC.js" type="text/javascript"></script><script src="/JS/popEvents.js" type="text/javascript"></script><script src="/PublishedContent/js/jquery.jplayer.min.js" type="text/javascript"></script><link rel="canonical" href="http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted" /><meta name="keywords" content="7.49,angiogenesis,antibody,apoptosis,immunotherapy,inhibitor,kinase,molecular,monoclonal,precision,Ras,signal,targeted, targets,therapies,therapy,treatment,trials,VEGF" /><meta name="description" content="A fact sheet that describes targeted cancer therapies, which are drugs that interfere with specific molecules involved in cancer cell growth and survival." /><meta name="content-language" content="en" /><meta name="english-linking-policy" content="http://www.cancer.gov/global/web/policies/exit" /><meta name="espanol-linking-policy" content="http://www.cancer.gov/espanol/global/politicas/salida" /><meta property="og:title" content="Targeted Cancer Therapies" /><meta property="og:description" content="A fact sheet that describes targeted cancer therapies, which are drugs that interfere with specific molecules involved in cancer cell growth and survival." /><meta property="og:type" content="Website" /><meta property="og:site_name" content="National Cancer Institute" /><meta property="og:url" content="http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted" /><meta name="twitter:card" content="summary" /></head>
<body id="Body1" class="cgvfactsheet">
<!-- CGov Container -->
<div id="cgovContainer"> 
<!-- Language Toggle -->
<div class="languageToggle" align="right">
<div id="LangList1">
	&nbsp;&nbsp;&nbsp;<a onclick="NCIAnalytics.ClickLink(this,'Language Select Spanish');" href="/espanol/recursos/hojas-informativas/tratamiento/terapias-dirigidas">Español</a>
</div>
</div>
  <!-- Site Banner -->
  <div class="skip"><a title="Skip to content" href="#skiptocontent">Skip to content</a></div>
  <div id="cgvSiteBanner">
	<div class="contentid-36963 slot-item only-SI">
		
<a name="top"></a><!-- BEGIN Logo and Search container --> <div id="logoandsearchcontainer"><!-- BEGIN NCI Logo --> <div id="NCILogo"><a href="/"><img alt="National Cancer Institute at the National Institutes of Health" height="82" src="/publishedcontent/images/images/design-elements/headers/nci-logo-english.gif" width="352" /></a></div><!-- END NCI Logo --> <!-- BEGIN Container for right side of banner --> <div id="bannerRight"><!-- BEGIN 1-800 Number --> <div id="questionsNumber"><a href="/global/contact" onclick="NCIAnalytics.QuestionsAboutCancerHeader(this);"><img alt="Questions About Cancer? 1-800-4-CANCER" height="47" src="/publishedcontent/images/images/banner-800-english.gif" width="281" /></a></div><!-- END 1-800 Number --> <!-- BEGIN Main Search --> <div id="mainSearch"><form action="/search/results" method="post" name="siteSearchForm" onsubmit="NCIAnalytics.SiteWideSearch(this);"><label class="hidden" for="swKeyword">Search</label> <input class="searchString" id="swKeyword" maxlength="255" name="swKeyword" onblur="bSearchBoxBool=false;" onfocus="bSearchBoxBool=true;" value="" /> <input alt="Search" class="searchSubmit" id="sitesearch" onclick="return siteSearchSubmit();" src="/publishedcontent/images/images/design-elements/headers/main-search-btn-english.gif" type="image" /></form></div><!-- END Main Search --></div><!-- END Container for right side of banner --></div><!-- END Logo and Search container -->
	</div>
</div>
  <div id="cgvMainNav">
	<div class="contentid-113330 slot-item only-SI">
		<ul class="genSiteMainNav genSiteMainNavEnglish">
			<li class="first nav-item-1"><a class="first" href="/"><span>NCI Home</span></a></li><li class="nav-item-2"><a class="current" href="/cancertopics"><span>Cancer Topics</span></a></li><li class="nav-item-3"><a class="" href="/clinicaltrials"><span>Clinical Trials</span></a></li><li class="nav-item-4"><a class="" href="/statistics"><span>Cancer Statistics</span></a></li><li class="nav-item-5"><a class="" href="/researchandfunding"><span>Research & Funding</span></a></li><li class="nav-item-6"><a class="" href="/newscenter"><span>News</span></a></li><li class="last nav-item-7"><a class="last" href="/aboutnci"><span>About NCI</span></a></li>
		</ul>
	</div>
</div>
  
  <!-- Content Header -->
  <div id="headerzone clearfix">
    <div id="cgvSlBreadcrumb">
	<div class="contentid-870117 slot-item only-SI">
		<ul class="breadcrumbs">
			<li><a href="/">Home</a></li><li><a href="/cancertopics">Cancer Topics</a></li><li><a href="/cancertopics/factsheet">Fact Sheets</a></li><li class="last-breadcrumb"><a href="/cancertopics/factsheet/Therapy">Cancer Therapy</a></li>
		</ul>
	</div>
</div> 
	<!--Page Options Bar-->
	<div class="page-options">
		<script type="text/javascript">
	var addthis_share = {
title: "Targeted Cancer Therapies",
description: "Describes targeted cancer therapies, drugs that  interfere with specific molecules involved in cancer cell growth and survival."}
</script><script type="text/javascript">
	var addthis_config = {
ui_language: "en",
ui_508_compliant: true}
</script><div id="PageOptionsControl1">
	<ul>
		<li class="po-print"><a title="Print" onclick="NCIAnalytics.PrintLink(this);" href="/cancertopics/factsheet/Therapy/targeted/print"><img alt="Print" src="/publishedcontent/images/images/spacer.gif" /></a></li><li class="po-email"><a title="Email" href="/common/popUps/PopEmail.aspx?title=Targeted+Cancer+Therapies&amp;docurl=%2fcancertopics%2ffactsheet%2fTherapy%2ftargeted&amp;language=en&amp;a=-1X660137351&amp;b=380c88" onclick="NCIAnalytics.eMailLink(this); dynPopWindow('/common/popUps/PopEmail.aspx?title=Targeted+Cancer+Therapies&amp;docurl=%2fcancertopics%2ffactsheet%2fTherapy%2ftargeted&amp;language=en&amp;a=-1X660137351&amp;b=380c88', 'emailPopUp', 'height=525,width=492'); return false;"><img alt="Email" src="/publishedcontent/images/images/spacer.gif" /></a></li><li class="po-facebook"><a class="addthis_button_facebook add_this_btn" title="Facebook" onclick="NCIAnalytics.BookmarkShareClick(this);" href="#"><img alt="Facebook" src="/publishedcontent/images/images/spacer.gif" /></a></li><li class="po-twitter"><a class="addthis_button_twitter add_this_btn" title="Twitter" onclick="NCIAnalytics.BookmarkShareClick(this);" href="#"><img alt="Twitter" src="/publishedcontent/images/images/spacer.gif" /></a></li><li class="po-googleplus"><a class="addthis_button_google_plusone_share add_this_btn" title="Google+" onclick="NCIAnalytics.BookmarkShareClick(this);" href="#"><img alt="Google+" src="/publishedcontent/images/images/spacer.gif" /></a></li><li class="po-pinterest"><a class="addthis_button_pinterest_share add_this_btn" title="Pinterest" onclick="NCIAnalytics.BookmarkShareClick(this);" href="#"><img alt="Pinterest" src="/publishedcontent/images/images/spacer.gif" /></a></li>
	</ul>
</div><script src="http://s7.addthis.com/js/250/addthis_widget.js#pubid=xa-4ed7cc9f006efaac" type="text/javascript">

</script>
	</div>
  </div>
  <div id="cgvLanguage">
	<div class="contentid-14059 slot-item only-SI">
		<div class="language-dates"></div>
	</div>
</div>
  <!-- Main Area --> 
  <!-- Left Navigation and Content Area -->
  <div id="mainContainer"> 
    <!-- Left Nav Column -->
    <div class="leftzone">
      
      
      <div id="cgvLeftNav" class="LeftNavSlot">
	<div class="contentid-22946 slot-item first-SI">
		<div class="leftnav-default"><h3>Search Fact Sheets by Keyword</h3><form onsubmit="NCIAnalytics.KeywordSearch(this,'/cancertopics/factsheet/fs-keyword-search');" method="post" name="NCSearchBox" action="/cancertopics/factsheet/fs-keyword-search"><label class="hidden" for="keyword">keyword</label>
                    <input id="keyword" class="search-go-english" name="keyword"><input
                    alt="Search" src="/images/red_go_button.gif" type="image" class="search-go-english-image"></form></div>
	</div><div class="contentid-36999 slot-item">
		<div class="leftnav-default"><h3>View Fact Sheets by Topic</h3><ul><li class="general-list-item">
<div class="title-and-desc">
<a href="/cancertopics/factsheet/Sites-Types">Cancer Type</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="/cancertopics/factsheet/Risk">Risk Factors and Possible Causes</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="/cancertopics/factsheet/prevention">Prevention</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="/cancertopics/factsheet/diet">Diet and Nutrition</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="/cancertopics/factsheet/detection">Detection and Diagnosis</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="/cancertopics/factsheet/Therapy">Cancer Therapy</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="/cancertopics/factsheet/clinicaltrials">Clinical Trials</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="/cancertopics/factsheet/Support">Support, Coping, and Resources</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="/cancertopics/factsheet/Tobacco">Tobacco and Smoking Cessation</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="/cancertopics/factsheet/NCI">About NCI</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="/cancertopics/factsheet/disparities">Cancer Health Disparities</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="/espanol/recursos/hojas-informativas">En espa&ntilde;ol</a></div>
</li>
</ul></div>
	</div><div class="contentid-37093 slot-item">

	</div><div class="contentid-109265 slot-item">
		<div class="leftnav-default"><h3>Popular Resources</h3><ul><li class="general-list-item">
<div class="title-and-desc">
<a href="/dictionary">NCI Dictionary of Cancer Terms</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="/drugdictionary">NCI Drug Dictionary</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="/clinicaltrials/search">Search for Clinical Trials</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="https://pubs.cancer.gov/ncipl/">NCI Publications</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="/espanol">Espa&ntilde;ol</a></div>
</li>
</ul></div>
	</div><div class="contentid-37066 slot-item last-SI">
		<div style=" padding: 6px 6px 4px 6px; border: 1px solid #cccccc;"><div class="rssSection"><a class="no-exit-notification" href="http://feeds.feedburner.com/ncictfeatured"><span class="rssRow">RSS Feed</span></a></div></div>
	</div>
</div>
      
    </div>
    <!-- End Left Nav --> 
    <!-- Main Content Area -->
    <div class="contentzone contentzone-defaultTemplateContentContainer"> <a id="skiptocontent" tabindex="1"></a>
      <div id="cgvPublicArchiveBannerSl">
	<div class="contentid-172410 slot-item only-SI">
		
	</div>
</div>
      
      
	  
      
      <article id="_article">
        <div id="cgvBody" class="cgvBody-defaultTemplateContentContainer">
	<div class="contentid-14059 slot-item only-SI">
		<div class="fact-and-question">
<h1>Targeted Cancer Therapies</h1><div class="keyPoints">
	<h3>Key Points</h3>
	<ul>
    		<li>Targeted cancer therapies are drugs or other substances that interfere with specific     molecules involved in cancer cell growth and survival. Traditional chemotherapy drugs,  by contrast, act against all actively dividing cells.</li>
					<li>Targeted cancer therapies that have been approved for use against specific cancers  include agents that prevent cell growth signaling, interfere with tumor blood vessel development, promote the death of cancer cells, stimulate the immune system to destroy  cancer cells, and deliver toxic drugs to cancer cells. </li>
				</ul>
</div>	
<div class="qnas">
	<ol class="qnas">
    		<li id='q1'><h3><p>What are targeted cancer therapies?</p></h3><p><p>Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045065&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045065&amp;version=Patient&amp;language=English'); return false;">molecules</a> ("molecular targets") that are involved in the growth, <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044078&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044078&amp;version=Patient&amp;language=English'); return false;">progression</a>, and spread of cancer. Targeted cancer therapies are sometimes called "molecularly targeted drugs," "molecularly targeted therapies," "precision medicines," or similar names.</p><p>Targeted therapies differ from standard <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045214&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=Patient&amp;language=English'); return false;">chemotherapy</a> in several ways:</p><ul><li>Targeted therapies act on specific molecular targets that are associated with cancer, whereas most standard chemotherapies act on all rapidly dividing normal and cancerous cells.</li><li>Targeted therapies are deliberately chosen or designed to interact with their target, whereas many standard chemotherapies were identified because they kill cells. </li><li>Targeted therapies are often <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000756173&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000756173&amp;version=Patient&amp;language=English'); return false;">cytostatic</a> (that is, they block tumor <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046479&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046479&amp;version=Patient&amp;language=English'); return false;">cell proliferation</a>), whereas standard chemotherapy agents are <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044020&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044020&amp;version=Patient&amp;language=English'); return false;">cytotoxic</a> (that is, they kill tumor cells). </li></ul><p>Targeted therapies are currently the focus of much anticancer drug development. They are a cornerstone of <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000741769&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000741769&amp;version=Patient&amp;language=English'); return false;">precision medicine</a>, a form of medicine that uses information about a person’s <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045693&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045693&amp;version=Patient&amp;language=English'); return false;">genes</a> and <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046092&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046092&amp;version=Patient&amp;language=English'); return false;">proteins</a> to prevent, diagnose, and treat disease.</p><p>Many targeted cancer therapies have been approved by the Food and Drug Administration (FDA) to treat specific types of cancer (see Questions 8 and 9). Others are being studied in <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045961&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045961&amp;version=Patient&amp;language=English'); return false;">clinical trials</a> (research studies with people), and many more are in preclinical testing (research studies with animals).</p></p></li>
					<li id='q2'><h3>How are targets for targeted cancer therapies identified?  </h3><p><p>The development of targeted therapies requires the identification of good targets—that is, targets that play a key role in cancer cell growth and survival. (It is for this reason that targeted therapies are sometimes referred to as the product of "rational" drug design.)<b><i>    </i></b></p><p>One approach to identify potential targets is to compare the amounts of individual <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046092&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046092&amp;version=Patient&amp;language=English'); return false;">proteins</a> in cancer cells with those in normal cells. Proteins that are present in cancer cells but not normal cells or that are more abundant in cancer cells would be potential targets, especially if they are known to be involved in cell growth or survival. An example of such a differentially expressed target is the <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044570&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044570&amp;version=Patient&amp;language=English'); return false;">human epidermal growth factor receptor 2 protein</a> (HER-2). HER-2 is expressed at high levels on the surface of some cancer cells. Several targeted therapies are directed against HER-2, including <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045439&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045439&amp;version=Patient&amp;language=English'); return false;">trastuzumab</a> (Herceptin®), which is approved to treat certain breast and stomach cancers that <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045812&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045812&amp;version=Patient&amp;language=English'); return false;">overexpress</a> HER-2.</p><p>Another approach to identify potential targets is to determine whether cancer cells produce mutant (altered) proteins that drive cancer <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044078&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044078&amp;version=Patient&amp;language=English'); return false;">progression</a>. For example, the cell growth signaling protein BRAF is present in an altered form (known as <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000721263&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000721263&amp;version=Patient&amp;language=English'); return false;">BRAF V600E)</a> in many <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045135&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045135&amp;version=Patient&amp;language=English'); return false;">melanomas</a>. <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000702051&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000702051&amp;version=Patient&amp;language=English'); return false;">Vemurafenib</a> (Zelboraf®) targets this mutant form of the BRAF protein and is approved to treat patients with <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000285970&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000285970&amp;version=Patient&amp;language=English'); return false;">inoperable</a> or <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044058&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044058&amp;version=Patient&amp;language=English'); return false;">metastatic</a> melanoma that contains this altered BRAF protein.</p><p>Researchers also look for abnormalities in <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046470&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046470&amp;version=Patient&amp;language=English'); return false;">chromosomes</a> that are present in cancer cells but not in normal cells. Sometimes these chromosome abnormalities result in the creation of a <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000613509&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000613509&amp;version=Patient&amp;language=English'); return false;">fusion gene</a> (a gene that incorporates parts of two different genes) whose product, called a <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044591&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044591&amp;version=Patient&amp;language=English'); return false;">fusion protein</a>, may drive cancer development. Such fusion proteins are potential targets for targeted cancer therapies. For example, <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044893&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044893&amp;version=Patient&amp;language=English'); return false;">imatinib mesylate</a> (Gleevec®) targets the <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000641107&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000641107&amp;version=Patient&amp;language=English'); return false;">BCR-ABL fusion protein</a>, which is made from pieces of two genes that get joined together in some <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045343&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045343&amp;version=Patient&amp;language=English'); return false;">leukemia</a> cells and promotes the growth of leukemic cells.</p></p></li>
					<li id='q3'><h3><p>How are targeted therapies developed?</p></h3><p><p>Once a candidate target has been identified, the next step is to develop a therapy that affects the target in a way that interferes with its ability to promote cancer cell growth or survival. For example, a <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000270742&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000270742&amp;version=Patient&amp;language=English'); return false;">targeted therapy</a> could reduce the activity of the target or prevent it from binding to a <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044958&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044958&amp;version=Patient&amp;language=English'); return false;">receptor</a> that it normally activates, among other possible mechanisms. </p><p>Most targeted therapies are either small molecules or <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046066&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046066&amp;version=Patient&amp;language=English'); return false;">monoclonal antibodies</a>. <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000653146&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000653146&amp;version=Patient&amp;language=English'); return false;">Small-molecule compounds</a> are typically developed for targets that are located inside the cell because such agents are able to enter cells relatively easily. Monoclonal antibodies are relatively large and generally cannot enter cells, so they are used only for targets that are outside cells or on the cell surface.</p><p>Candidate small molecules are usually identified in what are known as "high-throughput screens," in which the effects of thousands of test compounds on a specific target protein are examined. Compounds that affect the target (sometimes called "<a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000754026&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000754026&amp;version=Patient&amp;language=English'); return false;">lead compounds</a>") are then chemically modified to produce numerous closely related versions of the lead compound. These related compounds are then tested to determine which are most effective and have the fewest effects on nontarget molecules.</p><p>Monoclonal antibodies are developed by injecting animals (usually mice) with purified target proteins, causing the animals to make many different types of <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044918&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044918&amp;version=Patient&amp;language=English'); return false;">antibodies</a> against the target. These antibodies are then tested to find the ones that bind best to the target without binding to nontarget proteins.</p><p>Before monoclonal antibodies are used in humans, they are "<a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000470256&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000470256&amp;version=Patient&amp;language=English'); return false;">humanized</a>" by replacing as much of the mouse antibody molecule as possible with corresponding portions of human antibodies. Humanizing is necessary to prevent the human immune system from recognizing the monoclonal antibody as "<a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000698772&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000698772&amp;version=Patient&amp;language=English'); return false;">foreign</a>" and destroying it before it has a chance to bind to its target protein. Humanization is not an issue for small-molecule compounds because they are not typically recognized by the body as foreign.</p></p></li>
					<li id='q4'><h3><p>What types of targeted therapies are available?</p></h3><p><p>Many different targeted therapies have been approved for use in cancer treatment. These therapies include <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045110&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045110&amp;version=Patient&amp;language=English'); return false;">hormone therapies</a>, <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044829&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044829&amp;version=Patient&amp;language=English'); return false;">signal transduction inhibitor</a>s, <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000537335&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000537335&amp;version=Patient&amp;language=English'); return false;">gene expression</a> modulator, <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046524&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046524&amp;version=Patient&amp;language=English'); return false;">apoptosis</a> inducer, <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046739&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046739&amp;version=Patient&amp;language=English'); return false;">angiogenesis inhibitor</a>, <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045729&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045729&amp;version=Patient&amp;language=English'); return false;">immunotherapies</a>, and <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046622&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046622&amp;version=Patient&amp;language=English'); return false;">toxin</a> delivery molecules.</p><ul><li><b>Hormone therapies</b> slow or stop the growth of <span style=" background-color: #ffffff;">hormone-sensitive</span> <span style=" background-color: #ffffff;">tumors</span>, which require certain <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045713&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045713&amp;version=Patient&amp;language=English'); return false;">hormones</a> to grow. Hormone therapies act by preventing the body from producing the hormones or by interfering with the action of the hormones. Hormone therapies have been approved for both breast cancer and prostate cancer.</li><li><b>Signal transduction inhibitors</b> block the activities of molecules that participate in <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000597170&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000597170&amp;version=Patient&amp;language=English'); return false;">signal transduction</a>, the process by which a cell responds to signals from its environment. During this process, once a cell has received a specific signal, the signal is relayed within the cell through a series of <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044124&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044124&amp;version=Patient&amp;language=English'); return false;">biochemical reactions</a> that ultimately produce the appropriate response(s). In some cancers, the <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045772&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045772&amp;version=Patient&amp;language=English'); return false;">malignant</a> cells are stimulated to divide continuously without being prompted to do so by external <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045705&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045705&amp;version=Patient&amp;language=English'); return false;">growth factors</a>. Signal transduction inhibitors interfere with this inappropriate signaling.</li><li><b>Gene expression modulators</b> modify the function of proteins that play a role in controlling gene expression.</li><li><b>Apoptosis inducers</b> cause cancer cells to undergo a process of controlled cell death called apoptosis. Apoptosis is one method the body uses to get rid of unneeded or abnormal cells, but cancer cells have strategies to avoid apoptosis. Apoptosis inducers can get around these strategies to cause the death of cancer cells.</li><li><b>Angiogenesis inhibitors</b> block the growth of new <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045020&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045020&amp;version=Patient&amp;language=English'); return false;">blood vessels</a> to tumors (a process called tumor angiogenesis). A blood supply is necessary for tumors to grow beyond a certain size because blood provides the <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000538149&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000538149&amp;version=Patient&amp;language=English'); return false;">oxygen</a> and <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044697&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044697&amp;version=Patient&amp;language=English'); return false;">nutrients</a> that tumors need for continued growth. Treatments that interfere with angiogenesis may block tumor growth. Some targeted therapies that inhibit angiogenesis interfere with the action of <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044222&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044222&amp;version=Patient&amp;language=English'); return false;">vascular endothelial growth factor</a> (VEGF), a substance that stimulates new blood vessel formation. Other angiogenesis inhibitors target other molecules that stimulate new blood vessel growth.<b> </b></li><li><b>Immunotherapies</b> trigger the <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046356&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=Patient&amp;language=English'); return false;">immune system</a> to destroy cancer cells. Some immunotherapies are <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046066&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046066&amp;version=Patient&amp;language=English'); return false;">monoclonal antibodies</a> that recognize specific molecules on the surface of cancer cells. Binding of the monoclonal antibody to the target molecule results in the immune destruction of cells that express that target molecule. Other monoclonal antibodies bind to certain immune cells to help these cells better kill cancer cells.</li><li><b>Monoclonal antibodies that deliver toxic molecules</b> can cause the death of cancer cells specifically. Once the antibody has bound to its target cell, the toxic molecule that is linked to the antibody—such as a radioactive substance or a poisonous chemical—is taken up by the cell, ultimately killing that cell. The toxin will not affect cells that lack the target for the antibody—i.e., the vast majority of cells in the body.</li></ul><p><b><a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044952&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044952&amp;version=Patient&amp;language=English'); return false;">Cancer vaccines</a></b> and <b><a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045353&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045353&amp;version=Patient&amp;language=English'); return false;">gene therapy</a></b> are sometimes considered targeted therapies because they interfere with the growth of specific cancer cells. Information about these treatments can be found in the NCI fact sheets <a href="http://www.cancer.gov/cancertopics/factsheet/Therapy/cancer-vaccines"><i>Cancer Vaccines</i></a> and <a href="http://www.cancer.gov/cancertopics/factsheet/Therapy/biological"><i>Biological Therapies for Cancer</i></a>.</p></p></li>
					<li id='q5'><h3><p>How is it determined whether a patient is a candidate for targeted therapy? </p></h3><p><p>For some types of cancer, most patients with that cancer will have an appropriate target for a particular <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000270742&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000270742&amp;version=Patient&amp;language=English'); return false;">targeted therapy</a> and, thus, will be candidates to be treated with that therapy. <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044382&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044382&amp;version=Patient&amp;language=English'); return false;">CML</a> is an example: most patients have the <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000561237&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000561237&amp;version=Patient&amp;language=English'); return false;"><i>BCR-ABL</i> fusion gene</a>. For other cancer types, however, a patient’s tumor tissue must be tested to determine whether or not an appropriate target is present. The use of a targeted therapy may be restricted to patients whose tumor has a specific <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045693&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045693&amp;version=Patient&amp;language=English'); return false;">gene</a> <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046063&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046063&amp;version=Patient&amp;language=English'); return false;">mutation</a> that codes for the target; patients who do not have the mutation would not be candidates because the therapy would have nothing to target.</p><p>Sometimes, a patient is a candidate for a targeted therapy only if he or she meets specific criteria (for example, their cancer did not respond to other therapies, has spread, or is <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000285970&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000285970&amp;version=Patient&amp;language=English'); return false;">inoperable</a>). These criteria are set by the FDA when it approves a specific targeted therapy.</p></p></li>
					<li id='q6'><h3>What are the limitations of targeted cancer therapies?</h3><p><p>Targeted therapies do have some limitations. One is that cancer cells can become <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000416101&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000416101&amp;version=Patient&amp;language=English'); return false;">resistant</a> to them. Resistance can occur in two ways: the target itself changes through <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046063&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046063&amp;version=Patient&amp;language=English'); return false;">mutation</a> so that the <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000270742&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000270742&amp;version=Patient&amp;language=English'); return false;">targeted therapy</a> no longer interacts well with it, and/or the tumor finds a new pathway to achieve tumor growth that does not depend on the target.</p><p>For this reason, targeted therapies may work best in combination. For example, a recent study found that using two therapies that target different parts of the cell <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000561720&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000561720&amp;version=Patient&amp;language=English'); return false;">signaling pathway</a> that is <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044643&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044643&amp;version=Patient&amp;language=English'); return false;">altered</a> in <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045135&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045135&amp;version=Patient&amp;language=English'); return false;">melanoma</a> by the <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000721263&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000721263&amp;version=Patient&amp;language=English'); return false;">BRAF V600E mutation</a> slowed the development of resistance and <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045669&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045669&amp;version=Patient&amp;language=English'); return false;">disease progression</a> to a greater extent  than using just one targeted therapy (<a href="#r1">1</a>).    </p><p>Another approach is to use a targeted therapy in combination with one or more traditional <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045214&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=Patient&amp;language=English'); return false;">chemotherapy</a> drugs. For example, the targeted therapy <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045439&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045439&amp;version=Patient&amp;language=English'); return false;">trastuzumab</a> (Herceptin®) has been used in combination with <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045382&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045382&amp;version=Patient&amp;language=English'); return false;">docetaxel</a>, a traditional chemotherapy drug, to treat women with metastatic <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000444971&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000444971&amp;version=Patient&amp;language=English'); return false;">breast cancer</a> that <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045812&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045812&amp;version=Patient&amp;language=English'); return false;">overexpresses</a> the protein <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044945&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044945&amp;version=Patient&amp;language=English'); return false;">HER2/neu</a>.</p><p>Another limitation of targeted therapy at present is that drugs for some identified targets are difficult to develop because of the target’s structure and/or the way its function is regulated in the cell. One example is <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045859&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045859&amp;version=Patient&amp;language=English'); return false;">Ras</a>, a signaling protein that is <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044133&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044133&amp;version=Patient&amp;language=English'); return false;">mutated</a> in as many as one-quarter of all cancers (and in the majority of certain cancer types, such as <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044521&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044521&amp;version=Patient&amp;language=English'); return false;">pancreatic cancer</a>). To date, it has not been possible to develop inhibitors of Ras signaling with existing drug development technologies. However, promising new approaches are offering hope that this limitation can soon be overcome. </p></p></li>
					<li id='q7'><h3><p>What are the side effects of targeted cancer therapies? </p></h3><p><p>Scientists had expected that targeted cancer therapies would be less toxic than traditional <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045214&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=Patient&amp;language=English'); return false;">chemotherapy</a> drugs because cancer cells are more dependent on the targets than are normal cells. However, targeted cancer therapies can have substantial <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046580&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046580&amp;version=Patient&amp;language=English'); return false;">side effects</a>.</p><p>The most common side effects seen with targeted therapies are <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000306496&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000306496&amp;version=Patient&amp;language=English'); return false;">diarrhea</a> and liver problems, such as <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046371&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046371&amp;version=Patient&amp;language=English'); return false;">hepatitis</a> and elevated liver enzymes.  Other side effects seen with targeted therapies include:</p><ul><li>Skin problems (acneiform rash, dry skin, nail changes, hair depigmentation)</li><li>Problems with <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000476017&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000476017&amp;version=Patient&amp;language=English'); return false;">blood clotting</a> and wound healing</li><li>High blood pressure</li><li>Gastrointestinal perforation (a rare side effect of some targeted therapies)</li></ul><p>Certain side effects of some targeted therapies have been linked to better patient <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000467853&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000467853&amp;version=Patient&amp;language=English'); return false;">outcomes</a>.  For example, patients who develop acneiform rash (skin eruptions that resemble <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044183&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044183&amp;version=Patient&amp;language=English'); return false;">acne</a>) while being treated with the <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044829&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000044829&amp;version=Patient&amp;language=English'); return false;">signal transduction inhibitors</a> <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000508929&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000508929&amp;version=Patient&amp;language=English'); return false;">erlotinib</a> (Tarceva®) or <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000258356&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000258356&amp;version=Patient&amp;language=English'); return false;">gefitinib</a> (Iressa®), both of which target the <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045680&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045680&amp;version=Patient&amp;language=English'); return false;">epidermal growth factor receptor</a>, have tended to respond better to these drugs than patients who do not develop the rash (<a href="#r2">2</a>). Similarly, patients who develop high blood pressure while being treated with the <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046739&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046739&amp;version=Patient&amp;language=English'); return false;">angiogenesis inhibitor</a> <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046115&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000046115&amp;version=Patient&amp;language=English'); return false;">bevacizumab</a> generally have had better outcomes (<a href="#r3">3</a>).</p><p>The few targeted therapies that are approved for use in children can have different side effects in children than in adults, including <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045727&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045727&amp;version=Patient&amp;language=English'); return false;">immunosuppression</a> and impaired sperm production (<a href="#r4">4</a>).</p></p></li>
					<li id='q8'><h3><p>What targeted therapies have been approved for specific types of cancer?</p></h3><p><p>The FDA has approved targeted therapies for the treatment of some patients with the following types of cancer (some targeted therapies have been approved to treat more than one type of cancer):</p><p><b>Adenocarcinoma of the stomach or gastroesophageal junction</b>: <a href="http://www.cancer.gov/cancertopics/druginfo/trastuzumab">Trastuzumab (Herceptin®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/ramucirumab">ramucirumab (Cyramza™)</a></p><p><b>Basal cell carcinoma:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/vismodegib">Vismodegib (Erivedge™)</a></p><p><b>Brain cancer:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/bevacizumab">Bevacizumab (Avastin®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/everolimus">everolimus (Afinitor®)</a></p><p><b>Breast cancer:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/everolimus">Everolimus (Afinitor®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/tamoxifencitrate">tamoxifen</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/toremifene">toremifene (Fareston®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/trastuzumab">Trastuzumab (Herceptin®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/fulvestrant">fulvestrant (Faslodex®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/anastrozole">anastrozole (Arimidex®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/exemestane">exemestane (Aromasin®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/lapatinibditosylate">lapatinib (Tykerb®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/letrozole">letrozole (Femara®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/pertuzumab">pertuzumab (Perjeta™)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/ado-trastuzumab-emtansine">ado-trastuzumab emtansine (Kadcyla™)</a></p><p><b>Cervical cancer:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/bevacizumab">Bevacizumab (Avastin®)</a></p><p><b>Colorectal cancer:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/cetuximab">Cetuximab (Erbitux®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/panitumumab">panitumumab (Vectibix®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/bevacizumab">bevacizumab (Avastin®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/ziv-aflibercept">ziv-aflibercept (Zaltrap®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/regorafenib">regorafenib (Stivarga®)</a></p><p><b>Dermatofibrosarcoma protuberans:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/imatinibmesylate">Imatinib mesylate (Gleevec®)</a></p><p><b>Endocrine/neuroendocrine tumors:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/lanreotideacetate">Lanreotide acetate (Somatuline® Depot)</a></p><p><b>Head and neck cancer:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/cetuximab">Cetuximab (Erbitux®)</a></p><p><b>Gastrointestinal stromal tumor:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/imatinibmesylate">Imatinib mesylate (Gleevec®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/sunitinibmalate">sunitinib (Sutent®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/regorafenib">regorafenib (Stivarga®)</a></p><p><b>Giant cell tumor of the bone:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/denosumab">Denosumab (Xgeva®)</a></p><p><b>Kaposi sarcoma:</b> <a href="http://www.cancer.gov/drugdictionary/?CdrID=42147">Alitretinoin (Panretin®)</a></p><p><b>Kidney cancer:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/bevacizumab">Bevacizumab (Avastin®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/sorafenibtosylate">sorafenib (Nexavar®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/sunitinibmalate">sunitinib (Sutent®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/pazopanibhydrochloride">pazopanib (Votrient®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/temsirolimus">temsirolimus (Torisel®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/everolimus">everolimus (Afinitor®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/axitinib">axitinib (Inlyta®)</a></p><p><b>Leukemia:</b> <a href="http://www.cancer.gov/drugdictionary/?CdrID=41258">Tretinoin (Vesanoid®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/imatinibmesylate">imatinib mesylate (Gleevec®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/dasatinib">dasatinib (Sprycel®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/nilotinib">nilotinib (Tasigna®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/bosutinib">bosutinib (Bosulif®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/rituximab">rituximab (Rituxan®)</a><b>,</b> <a href="http://www.cancer.gov/cancertopics/druginfo/alemtuzumab">alemtuzumab (Campath®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/ofatumumab">ofatumumab (Arzerra®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/obinutuzumab">obinutuzumab (Gazyva™)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/ibrutinib">ibrutinib (Imbruvica™)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/idelalisib">idelalisib (Zydelig®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/fda-blinatumomab">blinatumomab (Blincyto™)</a></p><p><b>Liver cancer:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/sorafenibtosylate">Sorafenib (Nexavar®)</a></p><p><b>Lung cancer:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/bevacizumab">Bevacizumab (Avastin®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/crizotinib">crizotinib (Xalkori®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/erlotinibhydrochloride">erlotinib (Tarceva®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/gefitinib">gefitinib (Iressa®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/afatinibdimaleate">afatinib dimaleate (Gilotrif®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/ceritinib">ceritinib (LDK378/Zykadia)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/ramucirumab">ramucirumab (Cyramza™)</a></p><p><b>Lymphoma:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/ibritumomabtiuxetan">Ibritumomab tiuxetan (Zevalin®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/denileukindiftitox">denileukin diftitox (Ontak®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/brentuximabvedotin">brentuximab vedotin (Adcetris®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/rituximab">rituximab (Rituxan®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/vorinostat">vorinostat (Zolinza®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/romidepsin">romidepsin (Istodax®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/bexarotene">bexarotene (Targretin®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/bortezomib">bortezomib (Velcade®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/pralatrexate">pralatrexate (Folotyn®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/lenalidomide">lenaliomide (Revlimid®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/ibrutinib">ibrutinib (Imbruvica™)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/siltuximab">siltuximab (Sylvant™)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/idelalisib">idelalisib (Zydelig®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/belinostat">belinostat (Beleodaq™)</a></p><p><b>Melanoma:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/ipilimumab">Ipilimumab (Yervoy®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/vemurafenib">vemurafenib (Zelboraf®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/trametinib">trametinib (Mekinist®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/dabrafenib">dabrafenib (Tafinlar®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/fda-pembrolizumab">pembrolizumab (Keytruda®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/nivolumab">nivolumab (Opdivo®)</a></p><p><b>Multiple myeloma:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/bortezomib">Bortezomib (Velcade®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/carfilzomib">carfilzomib (Kyprolis®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/lenalidomide">lenaliomide (Revlimid®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/pomalidomide">pomalidomide (Pomalyst®)</a></p><p><b>Myelodysplastic/myeloproliferative disorders:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/imatinibmesylate">Imatinib mesylate (Gleevec®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/ruxolitinibphosphate">ruxolitinib phosphate (Jakafi™)</a></p><p><b>Ovarian epithelial/fallopian tube/primary peritoneal cancers:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/bevacizumab">Bevacizumab (Avastin®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/olaparib">olaparib (Lynparza™)</a></p><p><b>Pancreatic cancer:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/erlotinibhydrochloride">Erlotinib (Tarceva®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/everolimus">everolimus (Afinitor®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/sunitinibmalate">sunitinib (Sutent®)</a></p><p><b>Prostate cancer:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/cabazitaxel">Cabazitaxel (Jevtana®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/enzalutamide">enzalutamide (Xtandi®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/abirateroneacetate">abiraterone acetate (Zytiga®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/radium-223-dichloride">radium 223 chloride (Xofigo®)</a></p><p><b>Soft tissue sarcoma:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/pazopanibhydrochloride">Pazopanib (Votrient®)</a></p><p><b>Systemic mastocytosis:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/imatinibmesylate">Imatinib mesylate (Gleevec®)</a></p><p><b>Thyroid cancer:</b> <a href="http://www.cancer.gov/cancertopics/druginfo/cabozantinib-s-malate">Cabozantinib (Cometriq™)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/vandetanib">vandetanib (Caprelsa®)</a>, <a href="http://www.cancer.gov/cancertopics/druginfo/sorafenibtosylate">sorafenib (Nexavar®)</a></p></p></li>
					<li id='q9'><h3><p>Where can I find information about clinical trials of targeted therapies?</p></h3><p><p>Both FDA-approved and experimental targeted therapies for specific types of cancer are being studied in <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045961&amp;version=Patient&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000045961&amp;version=Patient&amp;language=English'); return false;">clinical trials</a>. The names of the targeted therapy types listed below are links to lists of ongoing clinical trials that are testing those types of targeted therapies in cancer patients. These trial descriptions can also be accessed directly by searching NCI’s <a href="http://www.cancer.gov/clinicaltrials/search">list of cancer clinical trials</a>. NCI’s list of cancer clinical trials includes all NCI-funded clinical trials as well as studies conducted by investigators at hospitals and medical centers throughout the United States and around the world.  For information about other ways to search the list, see "<a href="http://www.cancer.gov/clinicaltrials/search-form-help">Help Using the NCI Clinical Trials Search Form</a>." </p><p><a href="http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=12731149">Hormone therapy</a></p><p><a href="http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=12748503">Signal transduction inhibitors</a></p><p><a href="http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=12731168">Gene expression modulators</a></p><p><a href="http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=12731198">Apoptosis inducers</a></p><p><a href="http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=12731205">Angiogenesis inhibitors</a></p><p><a href="http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=12000577">Immunotherapy</a>                                 </p><p><a href="http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=12731216">Monoclonal antibody conjugates</a></p></p></li>
				</ol>
</div>	
<div class="fs-citations-list">
<h6>Selected References</h6>
	<ol class="citations-list">
<li id='r1'><p>Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. <i>New England Journal of Medicine</i> 2012; 367(18):1694-1703. </p> <a href="http://www.ncbi.nlm.nih.gov/pubmed/23020132">[PubMed Abstract]</a></li><li id='r2'><p>Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials. <i>Lung Cancer</i> 2012; 78(1):8-15. </p> <a href="http://www.ncbi.nlm.nih.gov/pubmed/22795701">[PubMed Abstract]</a></li><li id='r3'><p>Cai J, Ma H, Huang F, et al. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> 2013; 11:306.</p> <a href="http://www.ncbi.nlm.nih.gov/pubmed/24283603">[PubMed Abstract]</a></li><li id='r4'><p>Gore L, DeGregori J, Porter CC. Targeting developmental pathways in children with cancer: what price success? <i>Lancet Oncology</i> 2013; 4(2):e70-78.</p> <a href="http://www.ncbi.nlm.nih.gov/pubmed/23369685">[PubMed Abstract]</a></li></ol></div></div>

	</div>
</div>
      </article>
      <div id="cgvRelatedResourcesSl">
	<div class="contentid-14059 slot-item only-SI">
		<aside class="related-resources"><p>Related Resources</p><ul><li><a href="/cancertopics/factsheet/Therapy/angiogenesis-inhibitors">Angiogenesis Inhibitors</a></li><li><a href="/cancertopics/factsheet/Therapy/biological">Biological Therapies for Cancer</a></li><li><a href="/cancertopics/factsheet/clinicaltrials/clinical-trials">Cancer Clinical Trials</a></li><li><a href="/cancertopics/factsheet/Therapy/cancer-vaccines">Cancer Vaccines</a></li><li><a href="/cancertopics/factsheet/Therapy/hormone-therapy-breast">Hormone Therapy for Breast Cancer</a></li><li><a href="/cancertopics/factsheet/Therapy/hormone-therapy-prostate">Hormone Therapy for Prostate Cancer</a></li><li><a href="/researchandfunding/priorities/ras">The RAS Initiative</a></li></ul></aside>
	</div>
</div>
      
      <div id="cgvDate">
	<div class="contentid-14059 slot-item only-SI">
		




<div class="document-dates">
<ul class="clearfix">
<li><strong>Reviewed:</strong> April
 25, 2014</li>
</ul>
</div>

	</div>
</div>
      
      
      
      <!-- Begin Public Use Slot -->
      <div id="cgvPublicUseNoticeSl">
	<div class="contentid-260294 slot-item only-SI">
		<div class="public-use">
	<p>This text may be reproduced or reused freely. Please credit the National Cancer Institute as the source. Any graphics may be owned by the artist or publisher who created them, and <a href="/global/web/policies/copyright">permission</a> may be needed for their reuse.</p></div>

	</div>
</div>
      <!-- End Public Use Slot --> 
    </div>
    <!-- End Content Area --> 
  </div>
  <!-- End Left Navigation and Content Area --> 
  <!-- End Main Area --> 
  <!-- Footer -->
  <div id="cgvFooter" RemoveIfEmpty="false">
	<div class="contentid-36968 slot-item only-SI">
		<!-- BEGIN Footer --><div id="cgvSiteFooter"><ul id="findHelp"><li><a href="/global/contact" onclick="NCIAnalytics.QuestionsAboutCancerFooter(this);">We Can Answer Your Questions</a></li><li><strong>1-800-4-CANCER</strong></li><li><a href="https://livehelp.cancer.gov/" onclick="javascript:window.open('https://livehelp.cancer.gov/', 'LiveHelp','scrollbars=yes,resizable=yes,menubar=yes,toolbar=yes,location=yes,width=650,height=600'); return false;">LiveHelp Online Chat</a></li></ul><ul id="footerUtility"><li><a href="/" onclick="NCIAnalytics.FooterLink(this, 'NCI Home');">NCI Home</a></li><li><a href="/global/contact" onclick="NCIAnalytics.FooterLink(this, 'Contact Us');">Contact Us</a></li><li><a href="/global/web/policies" onclick="NCIAnalytics.FooterLink(this, 'Policies');">Policies</a></li><li><a href="/global/web/policies/accessibility" onclick="NCIAnalytics.FooterLink(this, 'Accessibility');">Accessibility</a></li><li><a href="/global/viewing-files" onclick="NCIAnalytics.FooterLink(this, 'Viewing Files');">Viewing Files</a></li><li><a href="/global/web/policies/foia" onclick="NCIAnalytics.FooterLink(this, 'FOIA');">FOIA</a></li><li><a href="/global/web/sitehelp" onclick="NCIAnalytics.FooterLink(this, 'Site Help');">Site Help</a></li><li class="last"><a href="/global/web/sitemap" onclick="NCIAnalytics.FooterLink(this, 'Site Map');">Site Map</a></li></ul><strong>Follow Us:</strong> <ul id="followUs"><li class="twitter"><a href="/global/newmedia#twitter" onclick="NCIAnalytics.FooterLink(this, 'Twitter');">Twitter</a></li><li class="youtube"><a class="no-exit-notification" href="http://www.youtube.com/ncigov" onclick="NCIAnalytics.FooterLink(this, 'YouTube');">YouTube</a></li><li class="facebook"><a href="/global/newmedia#facebook" onclick="NCIAnalytics.FooterLink(this, 'Facebook');">Facebook</a></li><li class="rss"><a href="/global/RSS" onclick="NCIAnalytics.FooterLink(this, 'RSS');">RSS</a></li></ul><p class="other-versions"><strong>Other Versions: <img alt="Mobile" src="/PublishedContent/Images/global/icon-mobile.png" style=" vertical-align: top;" /></strong> <a class="gray-text" href="http://m.cancer.gov" onclick="NCIAnalytics.FooterLink(this, 'Mobile');" style=" font-size: 11px;">Mobile</a> | <a class="gray-text" href="/espanol" onclick="NCIAnalytics.FooterLink(this, 'Espanol');" style=" font-size: 11px;">Español</a></p><ul id="agencyLinks"><li><a href="http://www.hhs.gov/">U.S. Department of Health and Human Services</a></li><li><a href="http://www.nih.gov/">National Institutes of Health</a></li><li><a href="http://www.cancer.gov/">National Cancer Institute</a></li><li class="last"><a href="http://www.usa.gov/">USA.gov</a></li></ul><div class="nih-tagline" style=" font-size: 12px;">NIH…Turning Discovery Into Health<sup>®</sup></div></div><!-- END Footer -->
	</div>
</div>
  <!-- End Foooter--> 
</div>
<!-- End CGovContainer--> 
<!-- TO INSERT WEB ANALYTICS CODE. Every template should have this 
    control else Web analytics scripts will not show up in the HTML-->

<!-- ***** NCI Web Analytics - DO NOT ALTER ***** -->
<script language="JavaScript" type="text/javascript">
<!--
var s_account='nciglobal,ncienglish-all,ncicancertopics';
-->
</script>
<script language="JavaScript" type="text/javascript" src="/JS/Omniture/NCIAnalyticsFunctions.js"></script>
<script language="JavaScript" type="text/javascript" src="/JS/Omniture/s_code.js"></script>
<script language="JavaScript" type="text/javascript">
<!--
s.channel='NCI Fact Sheets';
s.prop3='/cancertopics/factsheet/therapy/targeted';
s.prop6='Targeted Cancer Therapies';
s.prop8='english';
s.prop10=document.title;
s.prop25='05/12/2014';
s.eVar2='english';
s.events='event1';

var s_code=s.t();
if(s_code)
   document.write(s_code);
-->
</script>
<!-- ***** End NCI Web Analytics ***** -->


</body>
</html><script id="f5_cspm">(function(){var f5_cspm={f5_p:'NNFGEGOBMHPPGGFGDHOEDGNJIKDLEGNGNHJPIAMOMPHBMAALFFLMFCGGNGDAPEGEAAPCNBMLDDDCDIIPAAIONJNKPJLINHOIOBPKDLJLKJFHJFDBMKFLMMCKDAIDEOKB',setCharAt:function(str,index,chr){if(index>str.length-1)return str;return str.substr(0,index)+chr+str.substr(index+1);},get_byte:function(str,i){var s=(i/16)|0;i=(i&15);s=s*32;return((str.charCodeAt(i+16+s)-65)<<4)|(str.charCodeAt(i+s)-65);},set_byte:function(str,i,b){var s=(i/16)|0;i=(i&15);s=s*32;str=f5_cspm.setCharAt(str,(i+16+s),String.fromCharCode((b>>4)+65));str=f5_cspm.setCharAt(str,(i+s),String.fromCharCode((b&15)+65));return str;},set_latency:function(str,latency){latency=latency&0xffff;str=f5_cspm.set_byte(str,32,(latency>>8));str=f5_cspm.set_byte(str,33,(latency&0xff));str=f5_cspm.set_byte(str,27,2);return str;},wait_perf_data:function(){try{var wp=window.performance.timing;if(wp.loadEventEnd>0){var res=wp.loadEventEnd-wp.navigationStart;if(res<60001){var cookie_val=f5_cspm.set_latency(f5_cspm.f5_p,res);window.document.cookie='f5avraaaaaaaaaaaaaaaa='+encodeURIComponent(cookie_val)+';path=/';}
return;}}
catch(err){return;}
setTimeout(f5_cspm.wait_perf_data,100);return;},go:function(){var chunk=window.document.cookie.split(/\s*;\s*/);for(var i=0;i<chunk.length;++i){var pair=chunk[i].split(/\s*=\s*/);if(pair[0]=='f5_cspm'&&pair[1]=='1234')
{var d=new Date();d.setTime(d.getTime()-1000);window.document.cookie='f5_cspm=;expires='+d.toUTCString()+';path=/;';setTimeout(f5_cspm.wait_perf_data,100);}}}}
f5_cspm.go();}());</script>